Bounded definition
The cited source supports treating senolytic selectivity as a distinct method within the stated longevity and metabolism scope. Within this page, that proposition is limited to Limited to Senescent-cell survival pathways, compound screening, cell assays, and mouse experiments. in “The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs”; this candidate records the concept boundary and does not pool results from uncited systems or studies.
Definition and evidence boundary
A source-bounded method record for senolytic selectivity within longevity and metabolism. The bounded proposition retained by the canonical record is: The cited source supports treating senolytic selectivity as a distinct method within the stated longevity and metabolism scope.
The applicable scope is Limited to Senescent-cell survival pathways, compound screening, cell assays, and mouse experiments. in “The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs”; this candidate records the concept boundary and does not pool results from uncited systems or studies. This definition must not be generalized beyond the cited source and exact record boundary.
Claims: urn:maha:claim:longevity-metabolism-senolytic-selectivity
Mechanism and technical context
The study identifies candidate senolytic vulnerabilities and reports cell- and animal-model experiments for specified compounds. This is the source-bound technical context for the record; no uncited mechanism is added by the compiler.
Senolytic selectivity does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness. The mechanism or method is therefore presented as one component of a larger system, not as evidence for every downstream outcome.
Claims: urn:maha:claim:longevity-metabolism-senolytic-selectivity
How to interpret the evidence
No cross-source quantitative interval is asserted. Definitions, operating conditions, samples, instruments, and outcome measures must be checked against the exact cited locator during review. The evidence maturity recorded here is single study, and the claim kind is theoretical model.
Independent replication and cross-platform transfer have not been compiled for this candidate; the evidence maturity refers only to the bounded source contract. Preclinical selectivity and clearance results do not establish human safety, dosing, efficacy, or lifespan extension. These qualifications travel with the claim whenever it is reused.
Claims: urn:maha:claim:longevity-metabolism-senolytic-selectivity
What the source supports and what remains unknown
The inspected source supports exactly this: The study identifies candidate senolytic vulnerabilities and reports cell- and animal-model experiments for specified compounds. It was read at Senescent-cell survival pathways, compound screening, cell assays, and mouse experiments.
What remains unknown is everything outside that locator. Senolytic selectivity does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness. No quantity, comparison, or downstream outcome is established here unless a separately scoped record measures it.
Claims: urn:maha:claim:longevity-metabolism-senolytic-selectivity
Source identity, locator, and reuse boundary
The bound source is “The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs” by Yi Zhu, Tamara Tchkonia, Tamar Pirtskhalava, et al., published by Aging Cell on 2015-01-01; its declared stable identity is doi:10.1111/acel.12344.
The inspected-content locator is Senescent-cell survival pathways, compound screening, cell assays, and mouse experiments. Reuse is limited to citation-with-paraphrase. The candidate uses original boundary language and a short paraphrase linked to the cited source. No source passage, figure, or table is reproduced. This metadata establishes source identity and inspection scope, not the truth of claims outside the cited locator.
Claims: urn:maha:claim:longevity-metabolism-senolytic-selectivity
Comparison and calculation boundary
Applicability is decided explicitly, not filled with generic material.
This record carries 1 source-bound proposition and therefore has no second supported side. A comparison would have to be manufactured from an adjacent title rather than from a second inspected claim, which the gate forbids.
The canonical claim declares no reproducible numerical inputs, equation, units, or uncertainty propagation; recorded uncertainty kind is qualitative. Supplying sample values would invent an unsupported quantitative result.
Limitations and prohibited inference
The claim stops where its evidence stops.
- record boundary
Senolytic selectivity does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.
- record boundary
A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record.
- prohibited inference
Do not use this senolytic selectivity record to claim that the surrounding technology is proven, safe, scalable, commercially available, or strategically superior.
- prohibited inference
Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract.
- editorial
This compilation reorganizes an existing inspected claim and its declared source; it does not add a new experiment, measurement, or independent replication.
- editorial
Internal editorial inspection is not external peer review, and no result on this page has been independently reproduced.
Related records and mathematical bridges
Typed links expose context without asserting equivalence.
When no declared bridge edge is present, related records are linked by shared evidence or canonical domain adjacency. Those links are navigational and do not claim mathematical or physical equivalence.
Claim ledger
Every proposition keeps its own evidence state.
The cited source supports treating senolytic selectivity as a distinct method within the stated longevity and metabolism scope.
- Scope
- Limited to Senescent-cell survival pathways, compound screening, cell assays, and mouse experiments. in “The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs”; this candidate records the concept boundary and does not pool results from uncited systems or studies.
- Boundary
- Senolytic selectivity does not by itself establish system-level performance, safety, manufacturability, scalability, economic advantage, clinical benefit, or deployment readiness.
- Uncertainty
- No cross-source quantitative interval is asserted. Definitions, operating conditions, samples, instruments, and outcome measures must be checked against the exact cited locator during review.
- Replication
- Independent replication and cross-platform transfer have not been compiled for this candidate; the evidence maturity refers only to the bounded source contract.
Primary sources
Citation, locator, rights, and boundary travel together.
Source 1 · Aging Cell
The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs
Yi Zhu, Tamara Tchkonia, Tamar Pirtskhalava, et al.
- Exact locator
- Senescent-cell survival pathways, compound screening, cell assays, and mouse experiments.
- Establishes
- The study identifies candidate senolytic vulnerabilities and reports cell- and animal-model experiments for specified compounds.
- Boundary
- Preclinical selectivity and clearance results do not establish human safety, dosing, efficacy, or lifespan extension.
- Rights basis
- citation with paraphrase · The candidate uses original boundary language and a short paraphrase linked to the cited source. No source passage, figure, or table is reproduced.